Methods of treating cancer and inhibiting TYK2 and MEK
AssigneeWashington University
InventorsAngela Hirbe, Dana Borcherding, Neha Amin
Life of this patent
Estimating the term…
Abstract
Among the various aspects of the present disclosure is the provision of methods of treating cancer in a subject comprising administering a TYK2 inhibiting agent and a MEK inhibiting agent. In some embodiments, the subject has a malignant peripheral nerve sheath tumor (MPNST), neurofibromatosis Type 1 (NF1) cancer predisposition syndrome, benign plexiform neurofibromas (PN), or atypical neurofibromas (ANNUBP). Methods of inhibiting TYK2 and MEK in a subject in need thereof are also provided.
Claims4
A method of treating cancer comprising administering a synergistic amount of a TYK2 inhibiting agent and an MEK inhibiting agent, wherein the TYTK2 inhibiting agent comprises at least one of deucravacitinib and WU-12 and the MEK inhibiting agent comprises mirdametinib;
- and wherein the cancer is malignant peripheral nerve sheath tumor (MPNST).
Dependencies are inferred from the claim text.